Benzinga | May 20, 2021 06:17AM EDT

I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings

* I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG's (OTC: RHHBY) Tecentriq (atezolizumab) in patients with advanced cancer.

* An abstract detailing data from the trial will be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place next month.

* I-Mab touted a 23% objective response rate and disease control rate of 46% in the study among 13 evaluable patients with several different types of advanced cancers.

* A patient with ovarian cancer achieved a complete response; two others saw a partial response, while three had stable disease.

* In particular, investigators reported no "hook effect" in the Phase I trial, meaning the antibody potency seemed to increase proportionately with the dose rather than losing inhibition at a higher dose, an issue observed with certain other drugs in the class.

* The clinical activity was observed in both PD-(L)1 treatment na?ve and refractory cancer patients, including one partial response patient who previously failed Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab).

* The combination was safe and well-tolerated with no dose-limiting toxicity. All treatment-related adverse events were either mild or moderate.

* Price Action: IMAB shares closed at $63.46 on Wednesday.